Co-Diagnostics, Inc. (CODX) Stock

Co-Diagnostics, Inc. is a pioneering molecular diagnostics company specializing in the development, manufacturing, and global distribution of reagents essential for diagnostic tests. These tests operate by detecting and analyzing nucleic acid molecules, catering to a diverse range of applications in the United States and abroad.

The company's innovative product portfolio includes polymerase chain reaction (PCR) diagnostic tests designed for detecting COVID-19, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the Zika virus. Co-Diagnostics also offers multiplexed tests for identifying diseases carried by mosquitoes, alongside molecular tools crucial for infectious disease detection, liquid biopsy for cancer screening, and agricultural applications.

Co-Diagnostics, Inc. is at the forefront of technological advancement with its portable PCR device, designed to facilitate PCR testing in point-of-care and home settings. Beyond its proprietary developments, the company plans to expand its offerings by incorporating diagnostic equipment from other manufacturers into self-contained lab systems. Founded in 2013 and headquartered in Salt Lake City, Utah, Co-Diagnostics continues to drive innovation in molecular diagnostics, aiming to enhance global healthcare outcomes through advanced diagnostic solutions.